← All trials
NCT05514483
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2022
- Primary completion
- Mar 6, 2023
- Completion date
- May 6, 2023
- First posted
- Aug 24, 2022
- Last posted
- Nov 28, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MontrealLead sponsor
- University of MontrealReponsible party - principal investigator
- Government of CanadaCollaborator
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.